National Cancer Institute Awards $11.5M for Leukemia Research

OSU’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) has been awarded $11.5 million from the National Cancer Institute.  OSUCCC-James received the five-year Specialized Program Research Excellence award (SPORE) for the study and treatment of leukemia.  This is only the second NCI SPORE grant awarded for leukemia research.  The grant team, led by principal investigator, Dr. John C. Byrd and co-principal investigators Dr. Clara D. Bloomfield and Dr. Guido Marcucci, includes a number of prominent senior investigators at OSUCCC-James who have been working together for many years to improve prognostic factors and treatments for acute and chronic leukemias.

“This prestigious award will help an extraordinary team of accomplished cancer researchers at Ohio State’s Comprehensive Cancer Center engage in bedside and laboratory translational research of adult leukemia with the ultimate goal of improving clinical outcomes for patients,” said Dr. Michael A. Caligiuri, director of OSU’s CCC and CEO of The James. 

The OSUCCC-James is one of only five centers in the country with NCI approval to conduct both Phase I and Phase II clinical trials.   

For more on this award and how it will impact research and outcomes related to leukemia, see the story from OSU.